Some functional organs that have been developed in vitro include heart, kidney, and skin types.
New analysis from Frost & Sullivan (technicalinsights.frost.com), Advances in Replacement Organs and Tissue Replacement, finds that the scope of tissue engineering applications extends beyond typical cell-based therapies. The focus has shifted toward understanding organ formation that could substantially enhance the progress toward developing tissues and organs in vitro.
If you are interested in the study, which features an overview, summary, challenges, and latest coverage of advances in replacement organs and tissue replacement, please send an email to Christina Alfaro, Corporate Communications, at christina.alfaro[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country.
Advances in tissue engineering have come about mainly due to the need to control the shortage in organ supply and treat chronic wounds. As conventional wound-healing technologies relied on synthetic materials that required frequent replacement, there is a huge opportunity for tissue engineering technology that support the requirements of chronic wound healing.
"The future of tissue engineering lies in the fields of biomaterial scaffold applications (both static and resorbable) but more so in organ regeneration and cell-based applications," says Technical Insights Research Analyst Nandini Ishwarakrishnan. "This is because biomaterial applications will more or less serve a supportive function for tissue growth. Additionally, cell-based therapies and organ regeneration technology have the ability to offer organ substitutes and improved tissue layers to treat wounds of the skin and bone, creating a great market opportunity."
As the pace of research in biomaterial applications has outstripped that of cell therapy and organ regeneration, scientists in the tissue engineering space are working on enhancing the production of allogenic and stem cells through the development of bioreactor technologies. Such technological growth is vital to ensure the long-term application of the technology.
However, the use of cell therapy and organ regeneration to create synthetic organs comes with a set of challenges regarding increasing the scale of production, regulatory hurdles, and enhancing the proof of concept studies. More importantly, industry participants need to demonstrate the safety, quality and application of the technology in real time. Therefore, they are striving to establish clinical trial protocols and standard procedures for manufacturing.
"There are concerns regarding the application of skin graft, especially xenografts that could have serious impact on the histocompatibility of the tissue with the host," notes Technical Insights Research Analyst Bhuvaneashwar Subramanian. "Technically, this also remains a key challenge in terms of identifying the right kind of tissue that could be employed in case of injuries."
It is also crucial to associate tissue samples with the patient's blood groups to prevent any kind of immunogenic reactions and hence, companies provide immunosuppressants in most cases. Further, with allogenic sources, there exists considerable risk of infection by microbes.
"The best way to counter safety issues is to develop a set of industry-standard operating procedures and protocols that could be further segmented into research in cell-based therapies and biomaterial applications," observes Ishwarakrishnan. "Essentially, owing to variations in the practices across laboratories in the tissue engineering sector, there is bound to be some differences in the quality of the products that are generated and released."
Moreover, the lack of standard regulatory protocols is a reason for the longer time-to-market of several products. A set of standard regulatory principles that govern tissue engineering activity worldwide will hasten the process of tissue engineering, aiding progress in the field.
Advances in Replacement Organs and Tissue Replacement, a part of the Technical Insights subscription, provides an overview and outlook for tissue engineering technology. The study covers the biotechnology application and the drivers and challenges associated with the technology. Further, this research service includes detailed technology analysis and industry trends, evaluated following extensive interviews with market participants.
Technical Insights, a division of Frost & Sullivan, is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.
About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents.
Advances in Replacement Organs and Tissue Replacement / D12E